Physician profile
Bryan Ager
NPI 1306231907
$2,884.48
in general payments reported to CMS, 2019-2025
38 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $31.09 · 2024: $662 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $607.39 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $324.65 | 2023-2025 | Rybrevant, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $152.19 | 2024-2025 | |
| Abbvie INC. | $128.27 | 2025 | |
| Merck Sharp & Dohme LLC | $125.48 | 2024-2025 | Keytruda, Reblozyl, Lynparza |
| Reflexion Medical, INC. | $115.53 | 2022 | |
| Lilly USA, LLC | $100.33 | 2024-2025 | Verzenio |
| Glaxosmithkline, LLC. | $89.66 | 2025 | Zejula, Jemperli |
| Dendreon Pharmaceuticals LLC | $82.94 | 2025 | Provenge |
| Daiichi Sankyo INC. | $82.27 | 2024-2025 | Enhertu, Injectafer |
| Jazz Pharmaceuticals INC. | $78.31 | 2025 | |
| Iovance Biotherapeutics, INC. | $75.86 | 2025 | Amtagvi |
| Pfizer INC. | $63.55 | 2025 | |
| Tersera Therapeutics LLC | $58.57 | 2025 | Quzyttir, Xermelo |
| E.R. Squibb & Sons, L.L.C. | $58.19 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Ager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.